Amgen Says Strongly Disagrees With FDA's Proposal To Withdraw Tavneos From The U.S. Market
AMGN•Amgen responds to FDA withdrawal proposal
July 24 (Reuters) - Amgen Inc. AMGN.O:
- Amgen said it submits data to the FDA seeking a hearing on Tavneos (avacopan) in response to the withdrawal proposal.
- The company said it strongly disagrees with the FDA's proposal to withdraw Tavneos from the U.S. market.
Source text: [ID:]
Further company coverage: AMGN.O
